Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Abiomed

This article was originally published in The Gray Sheet

Executive Summary

Severe abdominal bleeding unrelated to the firm's AbioCor artificial heart caused the death of the first device recipient Nov. 30 after 151 days of use as part of an ongoing U.S. clinical trial, the firm states. Previous anticoagulant treatment also contributed to the death of the sixth AbioCor recipient from uncontrolled bleeding on Nov. 28. FDA cleared expansion of the trial from five to 10 patients on Nov. 26. Under the original IDE agreement, the U.S. AbioCor trial is expected to include three groups of five patients. The company expects to file a PMA in 2003...

You may also be interested in...



Abiomed To Show AbioCor Is Safe Enough For Healthier Patients

Abiomed is developing a smaller version of its artificial heart for the 65% of patients whose chest size is not large enough to accommodate the AbioCor device. The company recently began testing the Penn State Heart in animals and expectshuman implants to begin in 2004

Health And Wellness Trademark Review 31 March, 2020

Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.

Faster, Better? Fujitsu, Polarisqb 'Quantum-Inspired' Tech Speeds Discovery

Japanese ICT giant applies novel advanced computing techniques with a US venture partner to more rapidly identify lead molecules from a huge virtual space.

UsernamePublicRestriction

Register

MT015756

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel